ViGenCell News
News
0
Ticker
308080.KQ
ISIN
KR7308080001
ViGenCell Eulerpool News
ViGenCell Stock News
ViGenCell is being monitored by journalists and investors worldwide. We gather the latest ViGenCell news here.
ViGenCell Stock Press Releases
ViGenCell regularly publishes news on the company's website that are relevant for investors.
ViGenCell News 2026
This page contains all current news, analysis and press releases for ViGenCell stock (308080.KQ, ISIN: KR7308080001). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at ViGenCell.
ViGenCell Stock
ViGenCell ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea.